Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy

Journal of Crohn's and Colitis

Volumn 5, Issue 6, 2011, Pages 608-611

  Rojas Feria, Maria ^a   Eslam, Mohammed ^a   Castro Fernández, Manuel ^a   Guerrero, Pedro ^a   Larraona Moreno, Jose Luis ^a   Romero Gómez, Manuel ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Inflammatory bowel disease; Infliximab; Lymphoma

Indexed keywords

CD20 ANTIBODY; CD30 ANTIGEN; ETOPOSIDE; IMMUNOGLOBULIN G; INFLIXIMAB; LOMUSTINE; MESALAZINE; METHOTREXATE; PREDNISONE;

AGED; ARTICLE; CANCER RISK; CASE REPORT; CAUCASIAN; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FOLLOW UP; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCYTOPENIA; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEPTIC SHOCK; SKIN LYMPHOMA; SUPERINFECTION; ULCERATIVE COLITIS;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; COLITIS, ULCERATIVE; HODGKIN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; SKIN NEOPLASMS;

EID: 82255175193     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.04.015     Document Type: Article

References (24)

1. Danese S., Angelucci E. New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?. Gastroenterol Clin Biol 2009, 33(Suppl. 3):S217-S227.
2. Fiorino G., Rovida S., Correale C., Malesci A., Danese S. Emerging biologics in the treatment of inflammatory bowel disease: what is around the corner?. Curr Drug Targets 2010, 11(2):249-260.
3. Orlando A., Armuzzi A., Papi C., Annese V., Ardizzone S., Biancone L., Bortoli A., Castiglione F., D'Incà R., Gionchetti P., Kohn A., Poggioli G., Rizzello F., Vecchi M., Cottone M. Italian Society of Gastroenterology; Italian Group for the study of Inflammatory Bowel DiseaseBookmark. Dig Liver Dis 2011, 43(1):1-20.
4. Hoentjen F., van Bodegraven A.A. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009, 15(17):2067-2073.
5. Nakashima C., Tanioka M., Takahashi K., Miyachi Y. Diffuse large B-cell lymphoma in a patient with rheumatoid arthritis treated with infliximab and methotrexate. Clin Exp Dermatol 2008, 33:437-439.
6. Zeidan A., Sham R., Shapiro J., Baratta A., Kouides P. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy. Leuk Lymphoma 2007, 48:1410-1413.
7. Bucher C., Degen L., Dirnhofer S., Pless M., Herrmann R., Schraml P., Went P. Biologics in inflammatory disease: infliximab associated risk of lymphoma development. Gut 2005, 54:732-733.
8. Mahé E., Descamps V., Grossin M., Fraitag S., Crickx B. CD30+ T cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 2003, 149:170-173.
9. Vieites B., Avila R., Biscuola M., Carvajo F. Cutaneous Hodgkin-type lymphoproliferative lesion associated with immunomodulatory therapy for ulcerative colitis. J Cutan Pathol 2011, 38(5):443-447.
10. Biancone L., Orlando A., Kohn A., Colombo E., Sostegni R., Angelucci E., Rizzello F., Castiglione F., Benazzato L., Papi C., Meucci G., Riegler G., Petruzziello C., Mocciaro F., Geremia A., Calabrese E., Cottone M., Pallone F. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006, 55:228-233.
11. Gartlehner G., Hansen R.A., Jonas B.L., Thieda P., Lohr K.N. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. J Rheumatol 2006, 33(12):2398-2408.
12. Siegel C.A., Marden S.M., Persing S.M., Larson R.J., Sands B.E. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, 7(8):874-881.
13. Connell W.R., Kamm M.A., Dickson M., Balkwill A.M., Ritchie J.K., Lennard-Jones J.E. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994, 343:1249-1252.
14. Larvol L., Soule J.C., Le Tourneau A. Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease. N Engl J Med 1994, 331:883-884.
15. Kandiel A., Fraser A.G., Korelitz B.I., Brensinger C., Lewis J.D. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54(8):1121-1125.
16. Beigel F., Jürgens M., Tillack C., Subklewe M., Mayr D., Göke B., Brand S., Ochsenkühn T. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. Nat Rev Gastroenterol Hepatol 2009, 6(7):433-436.
17. Palli D., Trallori G., Bagnoli S., Saieva C., Tarantino O., Ceroti M., d'Albasio G., Pacini F., Amorosi A., Masala G. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000, 119:647-653.
18. Loftus E.V., Sandborn W.J. Lymphoma risk in inflammatory bowel disease: influences of referral bias and therapy. Gastroenterology 2001, 121:1239-1242.
19. Lewis J.D., Bilker W.B., Brensinger C., Deren J.J., Vaughn D.J., Strom B.L. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001, 121:1080-1087.
20. Wada N., Ikeda J., Hori Y., Fujita S., Ogawa H., Soma T., Sugiyama H., Fukuhara S., Kanamaru A., Hino M., Kanakura Y., Morii E., Aozasa K. Epstein-Barr virus in diffuse large B-Cell lymphoma in immunocompetent patients in Japan is as low as in Western Countries. J Med Virol 2011, 83(2):317-321.
21. Spacek M., Hubacek P., Markova J., Zajac M., Vernerova Z., Kamaradova K., Stuchly J., Kozak T. Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients. APMIS 2011, 119(1):10-16.
22. Van Hauwaert V., Meers S., Verhoef G., Vermeire S., Rutgeerts P., Van Assche G. Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis. J Crohns Colitis 2010, 4(6):683-686.
23. Chetty R., Hlatswayo N., Muc R., Sabaratnam R., Gatter K. Plasmablastic lymphoma in HIV+ patients: an expanding spectrum. Histopathology 2003, 42:605-609.
24. Vos A.C., Bakkal N., Minnee R.C., Casparie M.K., de Jong D.J., Dijkstra G., Stokkers P., van Bodegraven A.A., Pierik M., van der Woude C.J., Oldenburg B., Hommes D.W. for the Initiative on Crohn's and Colitis (ICC). Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis 2010 Dec 22.